Divided Dose of TRAVATAN®

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01298687

Recruitment Status : Completed

First Posted : February 18, 2011

Last Update Posted : May 5, 2017

Sponsor:

Information provided by (Responsible Party):

Alcon Research

Study Description

Brief Summary:

The purpose of this study is to compare the incremental dosing of travoprost ophthalmic solution versus once a day dosing of TRAVATAN® in lowering intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Condition or disease	Intervention/treatment	Phase
Open-angle Glaucoma Ocular Hypertension	Drug: Travoprost Ophthalmic Solution, 0.00013% Drug: Travoprost Ophthalmic Solution, 0.00033% Drug: Travoprost Ophthalmic Solution, 0.001% Drug: Travoprost Ophthalmic Solution, 0.00267% Drug: Travoprost Ophthalmic Solution, 0.004% Drug: Travoprost Vehicle	Phase 2

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	67 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Treatment
Study Start Date :	February 2011
Actual Primary Completion Date :	April 2011
Actual Study Completion Date :	April 2011

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Travoprost

Genetic and Rare Diseases Information Center resources: Pigment-dispersion Syndrome

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Trav 0.00013% Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days	Drug: Travoprost Ophthalmic Solution, 0.00013% Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
Experimental: Trav 0.00033% Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days	Drug: Travoprost Ophthalmic Solution, 0.00033% Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
Experimental: Trav 0.001% Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days	Drug: Travoprost Ophthalmic Solution, 0.001% Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
Experimental: Trav 0.00267% Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days	Drug: Travoprost Ophthalmic Solution, 0.00267% Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
Active Comparator: TRAVATAN Travoprost Ophthalmic Solution, 0.004%, 1 drop administered in each eye at 8 pm for 5 days, with 1 drop of vehicle administered at all other timepoints (2-hour intervals)	Drug: Travoprost Ophthalmic Solution, 0.004% Other Name: TRAVATAN®
Placebo Comparator: Vehicle Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days	Drug: Travoprost Vehicle Inactive ingredients used as an active comparator

Outcome Measures

Primary Outcome Measures :

24-hour Area Under the Curve (AUC) in IOP Reduction [ Time Frame: Day 5 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with open-angle glaucoma or ocular hypertension who meet the following IOP criteria:
1. Mean IOP ≥ 24 mmHg in at least 1 eye, with the same eye qualifying at 8 AM at both Day 0 and Day 1;
2. Mean IOP ≤ 36 mmHg in both eyes at all time points on Day 0 and Day 1.
Must sign an informed consent form.
Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

Females of childbearing potential who are pregnant, test positive on urine pregnancy test at the Screening Visit, intend to become pregnant during the study period, are breast-feeding, or are not using highly effective birth control measures.
Current or history of ocular inflammation or infection in either eye within the past 3 months.
Corneal thickness greater than 620 µm as determined by pachymetry in either eye.
Severe visual field loss.
Cup to disc ratio greater than 0.8 in either eye.
Intraocular surgery within the past 6 months in either eye.
Other protocol-defined exclusion criteria may apply.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01298687

Sponsors and Collaborators

Alcon Research

Investigators


Study Director:	Matt Walker, PhD	Alcon Research

More Information


Responsible Party:	Alcon Research
ClinicalTrials.gov Identifier:	NCT01298687 History of Changes
Other Study ID Numbers:	C-10-081
First Posted:	February 18, 2011 Key Record Dates
Last Update Posted:	May 5, 2017
Last Verified:	July 2014

Keywords provided by Alcon Research:


open-angle glaucoma ocular hypertension divided dose

Additional relevant MeSH terms:


Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases	Eye Diseases Pharmaceutical Solutions Ophthalmic Solutions Travoprost Antihypertensive Agents

To Top